AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31216226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6)
Number of subjects: 1873
Study 31216226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22)
Number of subjects: 1873
Study 31216226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus concurrent and maintenance bevacizumab (stage IV)
Number of subjects: 1873
Study 31216226 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control (n = 625)
Number of subjects: 1873
Study 31216226 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1/2 mutated carcinomas
Number of subjects: 1873
Study 31216226 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-BRCA1/2 HRR
Number of subjects: 1873
Study 27895192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (including Ca++-channel blockers and diuretics)
Number of subjects: 4290
Study 27895192 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4290
Study 27895192 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, female sex, higher average systolic blood pressure during follow-up, initial greater LV mass index
Number of subjects: 4290
Study 25880685 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus CMC 1% (n = 90)
Number of subjects: 180
Study 25880685 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (control group, n = 90)
Number of subjects: 180
Study 23719685 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions
Number of subjects: 207
Study 23719685 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions
Number of subjects: 207
Study 23719685 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions (good-fair overall condition)
Number of subjects: 207
Study 23719685 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions (good-fair overall condition)
Number of subjects: 207
Study 23719685 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy applied in 5 fractions (poor overall condition)
Number of subjects: 207
Study 23719685 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 20 fractions (poor overall condition)
Number of subjects: 207
Study 21855746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 112
Study 21855746 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study 19083208 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 35
Study 17416480 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cyclophosphamide (CYC)
Number of subjects: 37
Study 17416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 37
Study 17416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum creatinine > 150 μmol/L
Number of subjects: 37
Study 17416480 — intervention group
Group type: COMPARATOR
Intervention: Initial serum creatinine ≤ 150 μmol/L
Number of subjects: 37
Study 17416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal relapses
Number of subjects: 37
Study 17416480 — intervention group
Group type: COMPARATOR
Intervention: Initial route of CYC administration
Number of subjects: 37
Study 15543358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy with 0.625 mg of equine conjugated estrogens and 2.5 mg of medroxyprogesterone
Number of subjects: 15
Study 15543358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11167428 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 11167428 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 9590593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops (10 times)
Number of subjects: 50
Study 9590593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops (6 times)
Number of subjects: 50
Study 9590593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (200 mg)
Number of subjects: 50
Study 9590593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin (200 mg)
Number of subjects: 50
Study 8158887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 94
Study 8158887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30982687 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) plus standard of care
Number of subjects: 99
Study 30982687 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 99
Study 30982687 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 99
Study 28216244 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses of 2.7 x 10^5 PfSPZ at days 0, 28, 56, 84, and 140)
Number of subjects: 93
Study 28216244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 93
Study 28216244 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 93
Study 25894892 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (4.0-5.6 g day(-1))
Number of subjects: 27
Study 25894892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 27
Study 24033753 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Number of subjects: 15
Study 24033753 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 15
Study 21860557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium DASH diet (HSD)
Number of subjects: 101
Study 21860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium DASH diet (LSD)
Number of subjects: 101
Study 18199476 — intervention group
Group type: COMPARATOR
Intervention: Control etch-and-rinse adhesive
Number of subjects: 0
Study 18199476 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 0
Study 18199476 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0
Study 18199476 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 0
Study 17087307 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous implantation of bone marrow-mononuclear cells (BM-MNCs)
Number of subjects: 0
Study 17087307 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of bone marrow-derived or peripheral blood-derived endothelial progenitor cells (EPCs)
Number of subjects: 0
Study 17087307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell transplantation therapy
Number of subjects: 0
Study 14627786 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg once weekly)
Number of subjects: 652
Study 14627786 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 652
Study 14627786 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 652
Study 14627786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 10831972 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg three times daily for 6 months
Number of subjects: 20
Study 10831972 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75 mg depot every 28 days for 6 months
Number of subjects: 20
Study 10831972 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no treatment)
Number of subjects: 20
Study 9356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg before CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Number of subjects: 90
Study 9356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg after CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Number of subjects: 90
Study 9356085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg before CPB
Number of subjects: 90
Study 9356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg after CPB
Number of subjects: 90
Study 8210561 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial steroid pulses 500 mg x3 (n = 17)
Number of subjects: 30
Study 8210561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oral steroid treatment (n = 20)
Number of subjects: 30
Study 8210561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide pulses (n = 13)
Number of subjects: 30
Study 8210561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (n = 3)
Number of subjects: 30
Study 8210561 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchanges (used in 4 cases)
Number of subjects: 30
Study 3820944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine, 40 mg/kg
Number of subjects: 7
Study 3820944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal deferoxamine
Number of subjects: 7
Study 3820944 — intervention group
Group type: COMPARATOR
Intervention: Both intravenous and intraperitoneal deferoxamine
Number of subjects: 7
Study 3820944 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (both routes)
Number of subjects: 7
Study 30238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dairy protein supplementation
Number of subjects: 0
Study 30238801 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level nutrition behavior change education
Number of subjects: 0
Study 25827493 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 19
Study 25827493 — intervention group
Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 19
Study 24746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant add-on triple antiemetic therapy (with a 5-HT(3) receptor antagonist and dexamethasone)
Number of subjects: 134
Study 24746177 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy (5-HT(3) receptor antagonist and dexamethasone)
Number of subjects: 134
Study 24746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant add-on therapy in patients taking carboplatin and pemetrexed
Number of subjects: 134
Study 24746177 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy in patients taking carboplatin and pemetrexed
Number of subjects: 134
Study 23236685 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) coated mini implant
Number of subjects: 14
Study 23236685 — intervention group
Group type: COMPARATOR
Intervention: Plain mini implant (control)
Number of subjects: 14
Study 20932397 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Fuji IXGP Liquid diluted with water
Number of subjects: 6
Study 20932397 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Fuji IXGP Liquid (GC America)
Number of subjects: 6
Study 20932397 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated surfaces)
Number of subjects: 6
Study 18833900 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier methods of prevention; specific products not detailed; evidence examined in the article.
Number of subjects: 0
Study 16202050 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid 36%
Number of subjects: 15
Study 16202050 — intervention group
Group type: COMPARATOR
Intervention: Non-rinse conditioner (NRC)
Number of subjects: 15
Study 16202050 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbide bur
Number of subjects: 15
Study 16202050 — intervention group
Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 15
Study 12375460 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental crowns with different emergence profiles (up to 40 degrees)
Number of subjects: 6
Study 12375460 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral tooth)
Number of subjects: 6
Study 10206085 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 2 mg in the fasting state
Number of subjects: 12
Study 10206085 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone 2 mg following a standard high-fat breakfast
Number of subjects: 12
Study 7599049 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of serum markers for therapeutic response assessment
Number of subjects: 0
Study 7599049 — intervention group
Group type: COMPARATOR
Intervention: Conventional assessment methods (not specified)
Number of subjects: 0
Study 2189368 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diet
Number of subjects: 777
Study 2189368 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ventilated infants
Number of subjects: 777
Study 157810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tolbutamide
Number of subjects: 5
Study 157810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glibornuride
Number of subjects: 5
Study 31977129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio isolates
Number of subjects: 1440
Study 31977129 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic resistance
Number of subjects: 1440
Study 31977129 — intervention group
Group type: EXPERIMENTAL
Intervention: Virulence genes
Number of subjects: 1440
Study 31977129 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-resistant genes
Number of subjects: 1440
Study 31251102 — intervention group
Group type: EXPERIMENTAL
Intervention: Honokiol liposome injection (HKLI)
Number of subjects: 0
Study 29089756 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSVS (Central Nervous System Vital Signs) computerized cognitive test battery
Number of subjects: 220
Study 26601092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education through eight sessions by cardiology resident (Group A)
Number of subjects: 180
Study 26601092 — intervention group
Group type: COMPARATOR
Intervention: Self-care education through four pamphlets (Group B)
Number of subjects: 180
Study 26601092 — intervention group
Group type: COMPARATOR
Intervention: Self-care education through eight short message services (SMS) (Group C)
Number of subjects: 180
Study 26601092 — intervention group
Group type: COMPARATOR
Intervention: Usual care without self-care management training (Group D)
Number of subjects: 180
Study 26601092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education through eight sessions (Group A)
Number of subjects: 180
Study 24479703 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve conditions (mean pain score 2.3 ± 1.0)
Number of subjects: 20
Study 24479703 — intervention group
Group type: COMPARATOR
Intervention: Non-naïve conditions (mean pain score 2.2 ± 1.4)
Number of subjects: 20
Study 21078340 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention program (3 lessons in 5th grade and 3 lessons in 6th grade)
Number of subjects: 3173
Study 21078340 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3173
Study 19379611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation
Number of subjects: 127
Study 19379611 — intervention group
Group type: COMPARATOR
Intervention: Saline spray
Number of subjects: 127
Study 18178988 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks
Number of subjects: 119
Study 18178988 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 119
Study 15349784 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (12 g l(‐1) solution, 4 aliquots of 250 ml at 30 min intervals before exercise, additional 150 ml every 15 min during exercise)
Number of subjects: 8
Study 15349784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same volume and timing as BCAA)
Number of subjects: 8
Study 15349784 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 8
Study 15349784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11104347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 8
Study 11104347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9310273 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril, 6 mg once daily
Number of subjects: 251
Study 9310273 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 5-20 mg once daily
Number of subjects: 251
Study 9310273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 8339560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 1% ophthalmic ointment
Number of subjects: 25
Study 8339560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3554278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of compression and O-(beta-hydroxyethyl)-rutosides
Number of subjects: 107
Study 3554278 — intervention group
Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 107
Study 30830164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters + biomarkers (leptin + high molecular weight adiponectin + VEGF)
Number of subjects: 117
Study 30830164 — intervention group
Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 117
Study 29802398 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe OSA
Number of subjects: 1921
Study 29802398 — intervention group
Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 1921
Study 26780387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lenalidomide (15 mg/kg), docetaxel (75 mg/m²), and prednisone (10 mg daily)
Number of subjects: 63
Study 25280420 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 55
Study 25280420 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid
Number of subjects: 55
Study 25280420 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid
Number of subjects: 55
Study 23258727 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from a tutor
Number of subjects: 35
Study 23258727 — intervention group
Group type: COMPARATOR
Intervention: Self-learning tutorial
Number of subjects: 35
Study 21146655 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Number of subjects: 20245
Study 21146655 — intervention group
Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Number of subjects: 20245
Study 21146655 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin after 12 months of open-label thienopyridine treatment
Number of subjects: 20245
Study 17013969 — intervention group
Group type: EXPERIMENTAL
Intervention: FBCx
Number of subjects: 66
Study 17013969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16301700 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD-7
Number of subjects: 410
Study 16301700 — intervention group
Group type: COMPARATOR
Intervention: HAMD-17
Number of subjects: 410
Study 11976834 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with food (20 mg/m(2), orally)
Number of subjects: 12
Study 11976834 — intervention group
Group type: COMPARATOR
Intervention: 5-FU in fasted state (20 mg/m(2), orally)
Number of subjects: 12
Study 11976834 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with food and eniluracil
Number of subjects: 12
Study 10668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental expressed emotion (EE) levels in African American families
Number of subjects: 54
Study 10668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental expressed emotion (EE) levels in families with daughters
Number of subjects: 54
Study 10668624 — intervention group
Group type: COMPARATOR
Intervention: Parental expressed emotion (EE) levels in families with sons
Number of subjects: 54
Study 7756663 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine B (iron chelator)
Number of subjects: 81
Study 7756663 — intervention group
Group type: COMPARATOR
Intervention: Quinine + Placebo
Number of subjects: 81
Study 2101962 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.04 mg, p.o.)
Number of subjects: 21
Study 2101962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) (50 mg, i.v.) alone
Number of subjects: 21
Study 2101962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) (50 mg, i.v.) with Clenbuterol (0.04 mg, p.o.)
Number of subjects: 21
Study 428232 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T IUD
Number of subjects: 35496
Study 29886779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (I‐UCM)
Number of subjects: 102
Study 29886779 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 102
Study 31651319 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 1086
Study 31651319 — intervention group
Group type: COMPARATOR
Intervention: Being female
Number of subjects: 1086
Study 31651319 — intervention group
Group type: COMPARATOR
Intervention: Age 0-5 years
Number of subjects: 1086
Study 31651319 — intervention group
Group type: COMPARATOR
Intervention: Unknown HIV status
Number of subjects: 1086
Study 31651319 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary positive case
Number of subjects: 1086
Study 26483291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (3 months, 12 weekly sessions)
Number of subjects: 31
Study 26483291 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 26260350 — intervention group
Group type: EXPERIMENTAL
Intervention: Police Education Programme (PEP)
Number of subjects: 1200
Study 26260350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PEP and post-PEP surveys
Number of subjects: 1200
Study 23233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily + Temsirolimus 30 mg daily (5 days every 2 weeks)
Number of subjects: 1112
Study 23233719 — intervention group
Group type: COMPARATOR
Intervention: Letrozole + Placebo
Number of subjects: 1112